According to a market report by Lucintel, the future of the global oral protein and peptide market looks promising with opportunities in the gastric & digestive disorder, bone diseases, diabetes, and hormonal disorder markets. The global oral protein and peptide market is expected to grow with a CAGR of 11.7% from 2025 to 2031. The major drivers for this market are the increasing demand for protein-based supplements, the rising prevalence of metabolic disorders, and the growing focus on personalized nutrition solutions.A more than 150-page report to understand trends, opportunity and forecast in oral protein and peptide market to 2031 by drug type (linaclotide, plecanatide, calcitonin, insulin, and octreotide), application (gastric & digestive disorders, bone diseases, diabetes, and hormonal disorders), and region (North America, Europe, Asia Pacific, and the Rest of the World).
Lucintel forecasts that, within the drug type category, linaclotide is expected to witness the highest growth over the forecast period.
Within the application category, diabetes is expected to witness the highest growth.
Download sample by clicking on oral protein and peptide market
In terms of region, North America is expected to witness the highest growth over the forecast period.
Novo Nordisk A/S, Synergy Pharmaceuticals Inc., Oramed Pharmaceuticals Inc., Allergan Plc., Proxima Concepts Limited, Biocon Limited, Generex Biotechnology Corp., AstraZeneca PLC, Tarsa Therapeutics Inc., Chiasma Inc. are the major suppliers in the oral protein and peptide market.
This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or write us at [email protected] to get access of more than 1000 reports at fraction of cost visit Lucintel's Analytics Dashboard.
About Lucintel
At Lucintel, we offer solutions for you growth through game changer ideas and robust market & unmet needs analysis. We are based in Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20 years. We are quoted in several publications like the Wall Street Journal, ZACKS, and the Financial Times.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: [email protected]
Tel. +1-972-636-5056
Explore Our Latest Publications
Spatial Genomics & Transcriptomics Market
Subscriber Identification Module Card Market
Superconducting Material Market
Thermal Printable Wristband Market
Track and Trace Solution Market